pyrroles has been researched along with Bone Loss, Perimenopausal in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Laustsen, G; Wimmett, L | 1 |
| Barut, A; Sarikaya, S; Tanriverdi, HA | 1 |
| Arikan, O; Dokmetas, S; Yilmaz, A | 1 |
| Epstein, M; Laskey, R; Leary, E; Lowe, W; Reed, D; Zuckerman, A | 1 |
1 review(s) available for pyrroles and Bone Loss, Perimenopausal
| Article | Year |
|---|---|
2004 drug approval highlights: FDA update.
Topics: Administration, Cutaneous; Amlodipine; Anti-Bacterial Agents; Antidepressive Agents; Bronchodilator Agents; Cardiovascular Agents; Drug Approval; Drug Combinations; Duloxetine Hydrochloride; Eplerenone; Estradiol; Excitatory Amino Acid Antagonists; Female; Gastrointestinal Agents; Heptanoic Acids; Humans; Ketolides; Male; Memantine; Osteoporosis, Postmenopausal; Pyrroles; Rifamycins; Rifaximin; Scopolamine Derivatives; Spironolactone; Thiophenes; Tiotropium Bromide; United States | 2005 |
3 trial(s) available for pyrroles and Bone Loss, Perimenopausal
| Article | Year |
|---|---|
Statins have additive effects to vertebral bone mineral density in combination with risedronate in hypercholesterolemic postmenopausal women.
Topics: Atorvastatin; Bone Density; Bone Diseases, Metabolic; Cholesterol; Cholesterol, LDL; Drug Therapy, Combination; Etidronic Acid; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Pelvic Bones; Postmenopause; Pyrroles; Risedronic Acid | 2005 |
Effects of statins on bone mineral density.
Topics: Anticholesteremic Agents; Atorvastatin; Bone Density; Calcium; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lumbar Vertebrae; Male; Middle Aged; Osteocalcin; Osteoporosis, Postmenopausal; Prospective Studies; Pyrroles; Turkey | 2006 |
Atorvastatin does not induce glomerular or tubular dysfunction even at high doses.
Topics: Acetylglucosaminidase; Adult; Aged; Atorvastatin; beta 2-Microglobulin; Creatinine; Cystatin C; Cystatins; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Function Tests; Kidney Tubules; Middle Aged; Osteoporosis, Postmenopausal; Postmenopause; Pyrroles | 2007 |